Search PubMed⌕ Search

Biomedical subjects

Yu-ming Wang

Publications and source records attributed to Yu-ming Wang.

41 records · Page 3Linked to original sources
PubMed2003

[In vitro infection of human liver cancer cell line HepG2 with HCV].

BACKGROUND: To test susceptibility of human liver cell line Hep G2 to HCV in vitro. METHODS: Hep G2 was cultivated with the serum from a chronic hepatitis C patient. After inoculation, plus and minus strand of HCV RNA, the expression of HCV NS3 antigen and the location of HCV RNA in cell and/or supernatant were examined by RT-PCR, immunohistochemistry and in situ hybridization, respectively. RESULTS: HCV RNA could be detected from day 2 to day 40 post-inoculation in both cell and supernatant. HCV NS3 antigen could be expressed in infected cells and HCV RNA was mainly situated within cytoplasm. CONCLUSIONS: The results suggested that HepG2 cell line was not only susceptible to HCV but also could support its replication in vitro.

Carcinoma, Hepatocellular↗
PubMed2003

[Construction of the expression vectors of HDV ribozymes and their intracellular inhibiting activity against HCV RNA].

OBJECTIVES: To investigate whether HDV ribozymes can intracellularly inhibit HCV RNA. METHODS: The mammalian expression vectors, pC1-RzC1, pC1-RzC2 and pC1-RzC3, containing ribozymes cDNA of RzC1, RzC2, and RzC3, were constructed targeting different HCV-5' NCR-C RNA regions. Then the HCV-positive fetal hepatocytes were transfected with these plasmids using liposome-mediated method. The inhibitory effects of HDV ribozymes were evaluated by HCV RNA quantitation in cultured cells and the supernatants. RESULTS: (1) All the three HDV ribozymes were inserted into the expression vector. (2) Fetal hepatocytes were infected with HCV proven by RT-PCR and fluorescent quantitative PCR and expressed HCV NS3 and NS5 antigens by immunocytochemistry. (3) HDV ribozymes inhibited the activity of the target HCV RNA at expect positions in HCV-positive hepatocytes. At 0.5 micromol/L, the inhibitory rate of pC1-RzC1, pC1-RzC2, and pC1-RzC3 was 53.2%, 50.5 %, and 10.6% respectively. PC1-RzC1 was used continuously for one week, showing the inhibitory rate of 60.7%, 64.2%, 68.4%, 71.9%, 78.8% and 83.1% on the 2nd, 3rd, 4th, 5th, 6th and 7th day. CONCLUSION: The inhibitory activity of pC1-RzC1 (107-113nt) and pC1-RzC2 (268-274nt) is greater than that of pC1-RzC3 (345-351nt) in HCV-positive hepatocytes.

Genetic Therapy↗
PubMed2003

[Preliminary evaluation on the effects of a hybrid bioartificial liver support system in the treatment of hepatic failure].

OBJECTIVES: To construct a novel hybrid artificial liver support system and evaluate its clinical efficacy in the treatment of hepatic failure. METHODS: A hybrid bioartificial liver support system consisting of plasma exchange device, charcoal perfusion column, and bioreactor cultured human or porcine hepatocytes was developed. 30 patients with hepatic failure were treated using this hybrid system. RESULTS: Both the excellent rate and effectual rate of the artificial liver support system were 43.3% (13/30). The total effectual rate was 86.7%. Finally, eleven out of 30 patients recovered completely. Six patients were bridged to liver transplantation. Six patients (20%) died of hepatic failure and seven patients (23.3%) discharged due to worsening of disease. CONCLUSIONS: The hybrid artificial liver support system has prominent liver support effects for hepatic failure, which can be regarded as an efficient measure for the treatment of severe hepatitis.

Adult↗